Biotech Values

[Whalatane]

rfj. Starting from the baseline that you know far more about NASH then I probably ever will ....a question if U don't mind .
The placebo rates in the P2 study of VK2809 ( 2020 ) seem quite high ...% of patients experiencing >30% reduction in Liver fat ....22.2 % in the placebo arm ?
Am I understanding that correctly ?

Have you compared their data to ENTB's P2B ENLIVEN trial data .
I'd appreciate your analysis if U have time

I have a small position in VKTX . Waited until after their capital raise and then had to chase it higher :--(
Similar position in ETNB that I've held for longer

Kiwi